Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Vertex Pharma

- PMLiVE

Sandoz joins Europe’s MabThera biosimilar push

Novartis’ unit is second company to claim approval in Europe for biosimilar version

- PMLiVE

NICE relents on Kadcyla after Roche pricing negotiations

HER2-positive breast cancer therapy to be made available on the NHS in England

Roche Basel Switzerland

Roche trumpets APHINITY data, but did it hit the mark?

Results raise questions about benefit of combining Herceptin with Perjeta

Roche Basel Switzerland

Tecentriq bladder cancer approval in doubt after trial failure

The PD-L1 inhibitor failed to extend overall survival in a phase III study

Roche Basel Switzerland

Roche claims another FDA green light for Tecentriq

Wins approval for the treatment's first-line use in bladder cancer

Roche Basel Switzerland

Roche’s Alecensa beats Xalkori as first-line lung cancer therapy

Data shows ALK inhibitor reduces risk of disease worsening

Roche Basel Switzerland

Roche sets disruptive price for new MS drug Ocrevus in US

Firm will significantly under cut rivals like Merck's Rebif

- PMLiVE

Mylan deal with Roche clears path to biosimilar Herceptin launch

Covers global markets with the exception of Japan, Brazil and Mexico

Deal Watch February 2017

Actelion, Johnson & Johnson, Sanofi, Takeda and more feature in this month's pharma deals round-up

Roche Basel Switzerland

Patient death mars Roche haemophilia drug trial

Increases concerns over emicizumab’s safety profile with drug on course to file later this year

- PMLiVE

Mundipharma to launch first MabThera biosimilar in EU

EMA approves Truxima in all indications licensed to Roche’s cancer drug

- PMLiVE

Novartis’ Zykadia nears first-line lung cancer label

Hopes to boost slow second-line sales to compete directly with Pfizer’s Xalkori and Roche’s Alecensa 

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links